- TUBASTATIN A
-
-
2024-04-12
- CAS:1252003-15-8
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 2000ton
|
| | Tubastatin-A Basic information |
| Product Name: | Tubastatin-A | | Synonyms: | N-Hydroxy-4-[(1,2,3,4-tetrahydro-2-methyl-5H-pyrido[4,3-b]indol-5-yl)methyl]benzamide;N-hydroxy-4-((2-methyl-2,3,4,5-tetrahydro-1H-indeno[1,2-c]pyridin-5-yl)methyl)benzamide;N-Hydroxy-4-[(1,2,3,4-tetrahydro-2-methyl-5H-pyrido[4,3-b]indol-5-yl)methyl]benzamide Tubastatin A;Tubastatin A BASE;Tubastatin A(free base);N-hydroxy-4-((2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)methyl)benzamide;N-hydroxy-4-(2-methyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-ylmethyl)benzamide;N-Hydroxy-4-[(2-methyl-1,2,3,4-tetrahydro-5H-pyrido[4,3-b]indol-5 -yl)methyl]benzamide | | CAS: | 1252003-15-8 | | MF: | C20H21N3O2 | | MW: | 335.4 | | EINECS: | | | Product Categories: | Inhibitors | | Mol File: | 1252003-15-8.mol |  |
| | Tubastatin-A Chemical Properties |
| density | 1.28±0.1 g/cm3(Predicted) | | storage temp. | Sealed in dry,Store in freezer, under -20°C | | solubility | insoluble in EtOH; insoluble in H2O; ≥10.75 mg/mL in DMSO | | form | solid | | pka | 8.95±0.10(Predicted) | | color | Off-white to light yellow | | InChI | InChI=1S/C20H21N3O2/c1-22-11-10-19-17(13-22)16-4-2-3-5-18(16)23(19)12-14-6-8-15(9-7-14)20(24)21-25/h2-9,25H,10-13H2,1H3,(H,21,24) | | InChIKey | GOVYBPLHWIEHEJ-UHFFFAOYSA-N | | SMILES | C(NO)(=O)C1=CC=C(CN2C3=C(C=CC=C3)C3CN(C)CCC2=3)C=C1 |
| | Tubastatin-A Usage And Synthesis |
| Uses | Tubastatin A is a potent and selective HDAC6 inhibitor with an IC50 of 15 nM in a cell-free assay, and is selective (1000-fold more) against all other isozymes except HDAC8 (57-fold more). Tubastatin A also inhibits HDAC10 and metallo-β-lactamase domain-containing protein 2 (MBLAC2). | | Definition | ChEBI: A pyridoindole that is 1,2,3,4-tetrahydro-5H-pyrido[4,3-b]indole which is substituted on the tetrahydropyridine nitrogen by a methyl group and on the indole nitrogen by a p-[N-(hydroxy)aminoca
bonyl]benzyl group. It is a histone deacetylase 6 (HDAC6) inhibitor that is selective against all the other isozymes (1000-fold) except HDAC8 (57-fold). | | in vivo | Daily treatment of Tubastatin A at 0.5 mg/kg inhibits HDAC6 to promote Tregs suppressive activity in mouse models of inflammation and autoimmunity, including multiple forms of experimental colitis and fully major histocompatibility complex (MHC)-incompatible cardiac allograft rejection[2]. | | target | HDAC6 | | IC 50 | HDAC6: 15 nM (IC50); HDAC8: 854 nM (IC50); HDAC1: 16400 nM (IC50) | | References | [1] Kyle V. Butler et al. Rational Design and Simple Chemistry Yield a Superior, Neuroprotective HDAC6 Inhibitor, Tubastatin A J. Am. Chem. Soc., 2010, 132 (31), pp 10842-10846 DOI:10.1021/ja102758v
[2] Kozyreva VK, et al. NEDD9 regulates actin dynamics through cortactin deacetylation in an AURKA/HDAC6-dependent manner. Mol Cancer Res. 2014 May;12(5):681-93. DOI:10.1158/1541-7786.MCR-13-0654
[3] de Zoeten EF, et al. Histone deacetylase 6 and heat shock protein 90 control the functions of Foxp3(+) T-regulatory cells. Mol Cell Biol. 2011 May;31(10):2066-78. DOI:10.1128/MCB.05155-11
[4] Brijmohan, Angela, et al. Role of HDAC6 in Transcription Factor EB Mediated Clearance of Misfolded Proteins in Chronic Kidney Disease. University of Toronto.Nov-2017.
[5] Di Fulvio S, et al. Dysferlin interacts with histone deacetylase 6 and increases alpha-tubulin acetylation. PLoS One. 2011;6(12):e28563 DOI:10.1371/journal.pone.0028563
[6] Ketene AN, et al. Actin filaments play a primary role for structural integrity and viscoelastic response in cells. Integr Biol (Camb). 2012 May;4(5):540-9. DOI:10.1039/c2ib00168c
[7] Lechner S, Malgapo MIP, Grtz C, et al. Target deconvolution of HDAC pharmacopoeia reveals MBLAC2 as common off-target [published online ahead of print, 2022 Apr 28]. Nat Chem Biol. 2022;10.1038/s41589-022-01015-5. DOI:10.1038/s41589-022-01015-5
[8] Géraldy M, Morgen M, Sehr P, et al. Selective Inhibition of Histone Deacetylase 10: Hydrogen Bonding to the Gatekeeper Residue is Implicated. J Med Chem. 2019;62(9):4426-4443. DOI:10.1021/acs.jmedchem.8b01936
[9] Severin Lechner, et al. Target deconvolution of HDAC pharmacopoeia reveals MBLAC2 as common off-target. Nat Chem Biol. 2022 Apr 28. DOI:10.1038/s41589-022-01015-5 |
| | Tubastatin-A Preparation Products And Raw materials |
|